Vertex Pharmaceuticals (VRTX) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategic direction

• Leadership in cystic fibrosis (CF) continues, with expansion into heme, pain, and emerging renal verticals, supported by a robust R&D pipeline with five pivotal programs and several in phase II development.

• Diversification strategy established over a decade ago targets diseases with high unmet need, validated targets, and efficient regulatory pathways, aiming for a diversified pipeline and revenue base.

• Strong and growing balance sheet enables increased stock buybacks and continued focus on both internal and external innovation.

• Patent protection for key assets extends well into the 2030s, supporting long-term revenue stability.

Renal franchise and pipeline updates

• Pove in IgAN is on track for interim phase III data and regulatory submission in the first half of the year, with breakthrough designation and rolling FDA review underway.

• Phase II RUBY-3 data showed up to 64% protein reduction at 48 weeks; phase III RAINIER is placebo-controlled with similar design and endpoints.

• Safety focus centers on infection risk due to B cell modulation, with phase II data supporting a manageable benefit/risk profile.

• Pove offers once-monthly, low-volume, auto-injector dosing, and potential for multiple indications, positioning it as a market differentiator.

• Inaxaplin for APOL1-mediated kidney disease is in phase III, with interim results expected late this year or early next, and potential for accelerated approval if positive.

Cystic fibrosis franchise and competitive landscape

• Near-term CF growth driven by expansion to lower age groups, geographic markets, and broader mutation coverage with ALYFTREK.

• ALYFTREK recently gained reimbursement in Italy, expanding access to patients with ultra-rare mutations.

• Small molecule therapies remain the preferred approach for CF due to its systemic nature; next-generation candidates VX-828 and VX-581 show promising in vitro results.

• Commitment to further innovation in CF, aiming to surpass current standards even as unmet need diminishes.